Discover how AI-powered Trigger Alerts and integrated real-world data helped identify high-risk patients, equip field teams with timely clinical insights, and strengthen brand engagement strategies.
A top pharmaceutical manufacturer specializing in multiple myeloma needed a better way to identify newly diagnosed and relapsed high-risk patients, particularly those with specific genomic markers like t(4;14) or MMSET that were critical for appropriate therapy selection.
Relying on claims alone left them blind to the clinical nuance that determines eligibility, urgency, and treatment behavior. They lacked the depth, speed, and context to:
Their goal was to translate a highly targeted patient strategy into real-world brand execution, but without clinical visibility, opportunities were missed.
Norstella partnered with the brand to develop custom patient profiles using NorstellaLinQ’s tokenized, linked, and expert-curated real-world data, including unstructured EHR notes, lab results, and claims.
By combining rich clinical inputs and AI-driven processing, Norstella delivered a trigger alert solution designed to match the brand’s exact inclusion and exclusion criteria—ensuring outreach only occurred when patients met the right thresholds.
Key components included:
These alerts equipped field reps with timely, relevant reasons to engage HCPs, helping guide treatment conversations in real time.
With NorstellaLinQ, the manufacturer delivered more than 2,000 actionable Trigger Alerts and identified 800 newly diagnosed high-risk patients. There was a 90% provider match rate for confident, targeted outreach and improved alignment between brand strategy and field execution. Alerts guided HCP conversations based on real-time eligibility and patient status.
The initiative not only supported tactical execution, it validated the brand’s high-risk profile definition and opened doors for expanded use cases. Norstella’s depth of data unlocked clinical insights from EHR, labs, and claims that were not available through claims alone, and alerts were aligned to brand-specific inclusion/exclusion logic. Triggers were delivered within three to six days of a clinical encounter and supported future applications including segmentation, non-personal promotion, and omnichannel strategy.
Get Started
Frequently asked questions
AI-powered Trigger Alerts use integrated real-world data—including unstructured EHR notes, laboratory results and claims—to identify high-risk patients and notify pharmaceutical field teams when patients meet brand-specific clinical criteria.
Trigger Alerts combine AI-driven analytics with clinical data to identify newly diagnosed and relapsed patients based on biomarkers, lab values and disease staging, enabling more precise patient identification than claims data alone.
Trigger Alerts deliver timely, field-ready clinical insights mapped to treating providers, helping sales representatives engage healthcare professionals with relevant treatment information when patients become eligible for therapy.
Norstella delivered more than 2,000 actionable Trigger Alerts, identified 800 newly diagnosed high-risk patients, achieved a 90% provider match rate, and improved alignment between brand strategy and field execution.
By combining EHR notes, laboratory results and claims data, NorstellaLinQ uncovers clinical insights unavailable through claims alone, enabling more accurate patient identification, targeted HCP engagement and future omnichannel commercialization strategies.
